Hematologic Malignancies

Benign Hematology

Questions discussed in this category

How would you manage aplastic anemia refractory to multiple agents?

Treated initially with hATG/CNI/TPO, but then relapsed. Subsequently treated with cyclosporine, danazol, ESA, and alemtuzumab, but still with pancytop...

1 Answer available

What experience have you had with familial clustering of polycythemia vera?

Patient has a father and sister with both polycythemia vera with confirmed JAK2 V617F mutations. There is also suspicion for PV in a niece with pulmon...

1 Answer available

What is your clinical threshold for treating a potential monoclonal gammopathy of thrombotic significance?

New data suggests monoclonal gammopathies can be associated with thrombotic events. Is your practice changing to include monoclonal gammopathy evaluat...

1 Answer available

How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?

Are there specific guidelines for managing this patient population?

1 Answer available

Is bone marrow biopsy indicated in patients with primary polycythemia but negative for JAK2 mutation including exon 12?

2 Answers available

Would you give IV iron for low TSAT in patients with MDS anemia who are transfusion independent but on an ESA?

i.e. similar to CKD anemia?

1 Answer available

Would you consider using HMA in management of polycythemia vera?

i.e. treatment-refractory PV, prior to progression to PMF or AML

1 Answer available

What are contraindications for growth factors in patients with hematologic malignancies?

2 Answers available

In the absence of symptoms would you still treat high risk myelofibrosis if transplant ineligible?

Is leukocytosis and thrombocytosis alone an indication for treatment?

1 Answer available

Would you treat iron deficiency in post PV myelofibrosis if anemia is the predominant concern?

1 Answer available

In which patients with oncologic or hematologic disorders are you recommending a 3rd dose of mRNA COVID vaccine?

2 Answers available

What is the role, if any, for next generation sequencing testing in patients with suspected MPN who test negative for commonly identified mutations such as JAK2, CALR, MPL, and BCR-ABL?

3 Answers available

Do you consider splenic response as adequate to judge efficacy of JAK2 inhibitors in myeloproliferative disorders?

1 Answer available

Papers discussed in this category

Blood, 2016-01-21

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.

Ann Oncol, 2021 Mar 18

Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium.

Blood Adv, 2020 Dec 22

Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis.

European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2021 Dec 06

Antithrombotic Management in Adult Kidney Transplantation: A European Survey Study.

Nature, 2022 Jan 20

Life histories of myeloproliferative neoplasms inferred from phylogenies.

Leukemia research, 2024 Aug 25

Germline genetic variants that predispose to myeloproliferative neoplasms and hereditary myeloproliferative phenotypes.

Related Topics in Hematologic Malignancies